Navigation Links
Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma

Agilent Technologies Inc. (NYSE: A) today announced that its breakthrough Human Genome CGH Microarray technology will be used by researchers at Melbourne's Peter MacCallum Cancer Centre in a three-year study designed to better understand mesothelioma, a cancer found in the lining of the chest, the abdominal cavity and around the heart, usually caused by exposure to asbestos.

Due to its active mining and manufacturing of asbestos in the mid-1900s, Australia has the highest incidence of mesothelioma in the world. Rates of the disease have tripled in the past 20 years and are expected to peak about 2010. Diagnosis of this type of cancer is difficult, and patients are often not identified until the condition is quite advanced.

Agilent's new microarray techniques in comparative genomic hybridization (CGH) will allow researchers to rapidly and reliably identify genetic changes in tumorous cells. It is believed that specific genetic changes may accompany the onset and progression of the disease.

Dr. Andrew Holloway of the Peter MacCallum Cancer Centre said his team will work in conjunction with colleagues at The University of Western Australia, using Agilent's CGH microarray to provide a more thorough understanding of the genetic makeup of mesothelioma cells, which may ultimately lead to increased knowledge of the origins and development of this and other cancers.

"Agilent's CGH technology will allow us to study the entire genome in a manner that hasn't been possible in previous genomics research," said Holloway. "Upon completion, this project will produce the largest data set of its kind on mesothelioma in the world. We are very optimistic that it will give us a much clearer understanding and interpretation of this devastating disease."

"Agilent's new CGH microarray platform provides very high sensitivity, enabling researchers to detect small changes in chromosomes, including single copy deletions, which have previously been the most difficult to find," said Agilent Integrated Biology Solutions product manager David Tunks.

"We hope the outcome of this work will have a major effect on mesothelioma research," said Holloway. "The Australian economy will need $5 billion to fund the compensation, treatment and management of mesothelioma in the community, so this research is critical in working toward minimizing these costs, with the eventual hope of developing tools for earlier diagnosis and treatment."


'"/>

Source:Agilent


Related biology news :

1. Agilent Technologies releases automated literature search tool for biology researchers
2. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research
3. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
4. Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research
5. Agilent Technologies introduces high-capacity human protein removal system for proteomics research
6. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
7. Man and mouse share genome structures
8. Whole genome fine map of rice completed
9. Study finds more than one-third of human genome regulated by RNA
10. A bacterial genome reveals new targets to combat infectious disease
11. Scientists decipher genome of fungus that can cause life-threatening infections
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... -- Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for ... recent study published in STEM CELLS suggests that human neural stem cell (hNSC) ... to produce more neural cells. , Strategies involving transplantation of these cells ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
Breaking Biology Technology: